{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:02:48Z","timestamp":1784293368583,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mucosal melanoma is an aggressive malignancy with limited neoadjuvant options. We conducted a single arm, phase II study of neoadjuvant pembrolizumab plus lenvatinib followed by surgery and adjuvant pembrolizumab in resectable mucosal melanoma (NCT04622566) along with exploratory biomarker analysis. Primary objective was pathological complete response (pCR) rate; secondary endpoints included relapse-free survival (RFS), overall survival (OS), clinical response, surgical outcomes, and safety. Among 21 surgical patients, the pCR rate was 9.5%, major pathologic response (MPR) rate was 19.0%, and the pathologic response rate was 38.1%. Median RFS was 14.8 months (1-year rate: 61.9%); median OS was not reached. No grade 4\u20135 treatment-related toxicities or additional perioperative complications occcurred. Spatial profiling revealed a more immune-inflamed baseline microenvironment in responders, with activated CD4\u207a\/CD8\u207a T cell signatures associated with favorable outcomes. Treatment induced vascular normalization and increased T cell infiltration in non-responders, partially narrowing the immune gap. Responders exhibited higher prevalence of persistent TCR clonotypes and tighter spatial proximity between activated CD4\u207a and CD8\u207a T cells. Although the pre-specified primary endpoint was not met, our findings identify activated CD4\n                    <jats:sup>+<\/jats:sup>\n                    \/CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell states and TCR persistence as key outcome-associated features, supporting immune-informed optimization of peri-operative therapy in mucosal melanoma.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-73190-1","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:34:26Z","timestamp":1778891666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Lili","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-5688","authenticated-orcid":false,"given":"Lifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-7872","authenticated-orcid":false,"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-0975","authenticated-orcid":false,"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-0600","authenticated-orcid":false,"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2123-9761","authenticated-orcid":false,"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"73190_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680407","volume":"12","author":"L Mao","year":"2021","unstructured":"Mao, L., Qi, Z., Zhang, L., Guo, J. & Si, L. Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol. 12, 680407 (2021).","journal-title":"Front Immunol."},{"key":"73190_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaad.2016.08.007","volume":"76","author":"L Altieri","year":"2017","unstructured":"Altieri, L., Wong, M. K., Peng, D. H. & Cockburn, M. Mucosal melanomas in the racially diverse population of California. J. Am. Acad. Dermatol 76, 250\u2013257 (2017).","journal-title":"J. Am. Acad. Dermatol"},{"key":"73190_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/occmed\/kqn170","volume":"59","author":"C Young","year":"2009","unstructured":"Young, C. Solar ultraviolet radiation and skin cancer. Occup. Med. (Lond.) 59, 82\u201388 (2009).","journal-title":"Occup. Med. (Lond.)"},{"key":"73190_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"73190_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/path.4204","volume":"230","author":"SJ Furney","year":"2013","unstructured":"Furney, S. J. et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J. Pathol. 230, 261\u2013269 (2013).","journal-title":"J. Pathol."},{"key":"73190_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/path.5017","volume":"244","author":"J Lyu","year":"2018","unstructured":"Lyu, J. et al. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. J. Pathol. 244, 358\u2013366 (2018).","journal-title":"J. Pathol."},{"key":"73190_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.882471","volume":"13","author":"L Si","year":"2022","unstructured":"Si, L. et al. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study. Front Immunol. 13, 882471 (2022).","journal-title":"Front Immunol."},{"key":"73190_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","volume":"12","author":"L Si","year":"2019","unstructured":"Si, L. et al. A phase Ib study of pembrolizumab as second-line therapy for chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl. Oncol. 12, 828\u2013835 (2019).","journal-title":"Transl. Oncol."},{"key":"73190_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","volume":"119","author":"O Hamid","year":"2018","unstructured":"Hamid, O. et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br. J. Cancer 119, 670\u2013674 (2018).","journal-title":"Br. J. Cancer"},{"key":"73190_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus Placebo in Resected Stage III Melanoma. N. Engl. J. Med. 378, 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med"},{"key":"73190_CR11","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med"},{"key":"73190_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813\u2013823 (2023).","journal-title":"N. Engl. J. Med"},{"key":"73190_CR13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med"},{"key":"73190_CR14","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960\u20134967 (2018).","journal-title":"Clin. Cancer Res"},{"key":"73190_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","volume":"26","author":"JM Versluis","year":"2020","unstructured":"Versluis, J. M., Long, G. V. & Blank, C. U. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat. Med. 26, 475\u2013484 (2020).","journal-title":"Nat. Med"},{"key":"73190_CR16","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.3390\/curroncol30050360","volume":"30","author":"T Tachiiri","year":"2023","unstructured":"Tachiiri, T. et al. Vascular normalization caused by short-term lenvatinib could enhance transarterial chemoembolization in hepatocellular carcinoma. Curr. Oncol. 30, 4779\u20134786 (2023).","journal-title":"Curr. Oncol."},{"key":"73190_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212577","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFR\u03b2 complex in hepatocellular carcinoma. Front Immunol. 14, 1212577 (2023).","journal-title":"Front Immunol."},{"key":"73190_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.20.00902","volume":"39","author":"X Yan","year":"2021","unstructured":"Yan, X. et al. Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma. J. Clin. Oncol. 39, 881\u2013889 (2021).","journal-title":"J. Clin. Oncol."},{"key":"73190_CR19","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1093\/oncolo\/oyab068","volume":"27","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Efficacy and safety of apatinib in patients with recurrent or refractory melanoma. Oncologist 27, e463\u2013e470 (2022).","journal-title":"Oncologist"},{"key":"73190_CR20","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.1200\/jco.2013.31.15_suppl.9026","volume":"31","author":"S O\u2019Day","year":"2013","unstructured":"O\u2019Day, S. et al. A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. J. Clin. Oncol. 31, 9026\u20139026 (2013).","journal-title":"J. Clin. Oncol."},{"key":"73190_CR21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11912-022-01225-z","volume":"24","author":"S Zhang","year":"2022","unstructured":"Zhang, S., Zhang, J., Guo, J., Si, L. & Bai, X. Evolving treatment approaches to mucosal melanoma. Curr. Oncol. Rep. 24, 1261\u20131271 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"73190_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70169","volume":"15","author":"J Dai","year":"2025","unstructured":"Dai, J. et al. Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis. Clin. Transl. Med. 15, e70169 (2025).","journal-title":"Clin. Transl. Med"},{"key":"73190_CR23","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","volume":"37","author":"X Sheng","year":"2019","unstructured":"Sheng, X. et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G(4) monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. J. Clin. Oncol. 37, 2987\u20132999 (2019).","journal-title":"J. Clin. Oncol."},{"key":"73190_CR24","doi-asserted-by":"crossref","unstructured":"Li S, et al. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J. Immunother. Cancer 10, e004036 (2022).","DOI":"10.1136\/jitc-2021-004036"},{"key":"73190_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial. Signal Transduct. Target Ther. 9, 318 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"73190_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.annonc.2023.10.793","volume":"35","author":"B Lian","year":"2024","unstructured":"Lian, B. et al. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann. Oncol. 35, 211\u2013220 (2024).","journal-title":"Ann. Oncol."},{"key":"73190_CR27","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw694","volume":"28","author":"B Lian","year":"2017","unstructured":"Lian, B. et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann. Oncol. 28, 868\u2013873 (2017).","journal-title":"Ann. Oncol."},{"key":"73190_CR28","doi-asserted-by":"publisher","first-page":"adv00502","DOI":"10.2340\/00015555-3832","volume":"101","author":"SS Ertekin","year":"2021","unstructured":"Ertekin, S. S. et al. Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence. Acta Derm. Venereol. 101, adv00502 (2021).","journal-title":"Acta Derm. Venereol."},{"key":"73190_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/01.coc.0000170805.14058.d3","volume":"28","author":"WM Mendenhall","year":"2005","unstructured":"Mendenhall, W. M. et al. Head and neck mucosal melanoma. Am. J. Clin. Oncol. 28, 626\u2013630 (2005).","journal-title":"Am. J. Clin. Oncol."},{"key":"73190_CR30","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","volume":"19","author":"B Lian","year":"2013","unstructured":"Lian, B. et al. Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin. Cancer Res. 19, 4488\u20134498 (2013).","journal-title":"Clin. Cancer Res"},{"key":"73190_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.annonc.2022.07.002","volume":"33","author":"B Lian","year":"2022","unstructured":"Lian, B. et al. Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann. Oncol. 33, 1061\u20131070 (2022).","journal-title":"Ann. Oncol."},{"key":"73190_CR32","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria, R. N. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 20, e378\u2013e389 (2019).","journal-title":"Lancet Oncol."},{"key":"73190_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.22.00221","volume":"41","author":"A Arance","year":"2023","unstructured":"Arance, A. et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J. Clin. Oncol. 41, 75\u201385 (2023).","journal-title":"J. Clin. Oncol."},{"key":"73190_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/1078-0432.CCR-20-3285","volume":"27","author":"KL Mueller","year":"2021","unstructured":"Mueller, K. L. et al. Neoadjuvant therapy for melanoma: a U.S. food and drug administration-melanoma research alliance public workshop. Clin. Cancer Res. 27, 394\u2013401 (2021).","journal-title":"Clin. Cancer Res"},{"key":"73190_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ygyno.2022.11.013","volume":"168","author":"T Shu","year":"2023","unstructured":"Shu, T. et al. Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer. Gynecol. Oncol. 168, 135\u2013143 (2023).","journal-title":"Gynecol. Oncol."},{"key":"73190_CR36","doi-asserted-by":"publisher","unstructured":"Mao, L. et al. A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.19847960 (2026).","DOI":"10.5281\/zenodo.19847960"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73190-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:02:58Z","timestamp":1784289778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73190"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73190-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Li. is employee of Geneplus-Beijing. L.Si has received speakers\u2019 honoraria from OrienGene, Shanghai Junshi Biosciences, MSD, Novartis, and Roche. J.G. has consulting or advisory roles in Oriengene, Shanghai Junshi Biosciences, Simcere Pharmaceutical Group, Novartis, MSD, Bayer, Roche, and Pfizer. No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6491"}}